Market Cap 3.24B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 1,083,500
Avg Vol 1,510,584
Day's Range N/A - N/A
Shares Out 96.37M
Stochastic %K 63%
Beta 0.21
Analysts Strong Sell
Price Target $85.85

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
outlawinvestor1
outlawinvestor1 Oct. 24 at 3:15 AM
$RZLT i was thinking through who may be the most likely acquirer. my guess based on recent bod and mgmt team additions is that it's $RARE. sunil karnawat joined in august 2025 as cco. prior to this, he was an exec at ultragenyx from 2017-2024. erik harris joined the bod in march 2025 and currently serves as cco of ultragenyx. the question i have is how they would structure this deal. ultragenyx doesn't have a lot of cash, but quite a bit of debt. thus, they likely wouldn't be able to do an all-cash deal funded with additional debt. so it would need to likely be cash + stock + contingent payments. i would much rather it be $LLY $NVO $TAK but signs don't point to any of these companies.
1 · Reply
Pharma3000
Pharma3000 Oct. 22 at 10:50 AM
$RARE its crazy what catalyst they have the next 3-4 months. Like UX111 Resubmission, DTX401 BLA and read out of UX143
0 · Reply
Berakhot
Berakhot Oct. 21 at 8:55 PM
$RARE $MREO Woooot woooooot... great find OutPerformGER!
1 · Reply
Cryptojoe9
Cryptojoe9 Oct. 20 at 10:53 AM
$RARE 55 soon
0 · Reply
OutperformGER
OutperformGER Oct. 19 at 2:43 PM
$RARE is hiring a Sr. Director Global medical lead - bone for OI ($MREO) https://job-boards.greenhouse.io/ultragenyxpharmaceutical/jobs/4618943005?gh_jid=4618943005&gh_src=6eqdexj45us
2 · Reply
commanche
commanche Oct. 12 at 3:14 AM
$RARE when is the next catalyst again?
2 · Reply
CagedMoney
CagedMoney Oct. 11 at 8:01 PM
$RARE Easy 5% next week
0 · Reply
Masonsy
Masonsy Oct. 9 at 1:59 PM
$RARE I heard good news is coming soon
1 · Reply
commanche
commanche Oct. 7 at 12:54 AM
$RARE hmmm.. this might not be short term gain. Out for now to fund other opp
1 · Reply
MadMaverick
MadMaverick Oct. 4 at 2:47 PM
Based on my weekly chart and my custom indicator. $RARE is setting up over $32.
0 · Reply
Latest News on RARE
Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 2 months ago

Ultragenyx to Participate at Investor Conferences in September


Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 6 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline


Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 8 months ago

Ultragenyx to Participate at Investor Conferences in March


Ultragenyx to Participate in Investor Conferences in December

Nov 26, 2024, 4:30 PM EST - 11 months ago

Ultragenyx to Participate in Investor Conferences in December


Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12, 2024, 11:12 AM EST - 1 year ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat


outlawinvestor1
outlawinvestor1 Oct. 24 at 3:15 AM
$RZLT i was thinking through who may be the most likely acquirer. my guess based on recent bod and mgmt team additions is that it's $RARE. sunil karnawat joined in august 2025 as cco. prior to this, he was an exec at ultragenyx from 2017-2024. erik harris joined the bod in march 2025 and currently serves as cco of ultragenyx. the question i have is how they would structure this deal. ultragenyx doesn't have a lot of cash, but quite a bit of debt. thus, they likely wouldn't be able to do an all-cash deal funded with additional debt. so it would need to likely be cash + stock + contingent payments. i would much rather it be $LLY $NVO $TAK but signs don't point to any of these companies.
1 · Reply
Pharma3000
Pharma3000 Oct. 22 at 10:50 AM
$RARE its crazy what catalyst they have the next 3-4 months. Like UX111 Resubmission, DTX401 BLA and read out of UX143
0 · Reply
Berakhot
Berakhot Oct. 21 at 8:55 PM
$RARE $MREO Woooot woooooot... great find OutPerformGER!
1 · Reply
Cryptojoe9
Cryptojoe9 Oct. 20 at 10:53 AM
$RARE 55 soon
0 · Reply
OutperformGER
OutperformGER Oct. 19 at 2:43 PM
$RARE is hiring a Sr. Director Global medical lead - bone for OI ($MREO) https://job-boards.greenhouse.io/ultragenyxpharmaceutical/jobs/4618943005?gh_jid=4618943005&gh_src=6eqdexj45us
2 · Reply
commanche
commanche Oct. 12 at 3:14 AM
$RARE when is the next catalyst again?
2 · Reply
CagedMoney
CagedMoney Oct. 11 at 8:01 PM
$RARE Easy 5% next week
0 · Reply
Masonsy
Masonsy Oct. 9 at 1:59 PM
$RARE I heard good news is coming soon
1 · Reply
commanche
commanche Oct. 7 at 12:54 AM
$RARE hmmm.. this might not be short term gain. Out for now to fund other opp
1 · Reply
MadMaverick
MadMaverick Oct. 4 at 2:47 PM
Based on my weekly chart and my custom indicator. $RARE is setting up over $32.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 10:02 AM
$RARE: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $40 Exp on 01/16/2026 with Premium of $27K and showing NEUTRAL Sentiment
0 · Reply
notreload_ai
notreload_ai Oct. 2 at 12:49 PM
JPMorgan is optimistic about $RARE's drug setrusumab (UX143) and expects big gains ahead of key study updates. https://notreload.xyz/ultragenyx-positive-catalyst-watch-jpmorgan-analysis/
0 · Reply
lidopete
lidopete Oct. 2 at 12:32 PM
$MREO $RARE Ultragenyx placed on 'Positive Catalyst Watch' at JPMorgan JPMorgan analyst Anupam Rama placed shares of Ultragenyx on "Positive Catalyst Watch" ahead of the company's ORBIT and COSMIC study updates. The firm has confidence in setrusumab's clinical success and keeps an Overweight rating on the shares with a $125 price target. At current share levels, JPMorgan sees a "very positive" reward/risk profile heading into the updates with more win scenarios than downside scenarios. Note, MREO is RARE's partner with setrusumab
1 · Reply
xbibackto65s
xbibackto65s Oct. 1 at 4:28 PM
$RARE what a pos always down even when $XBI is flying
1 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 1 at 12:41 PM
0 · Reply
research_WTR
research_WTR Oct. 1 at 9:58 AM
Did you catch Dmitry Silversteyn recap from Part 2 of his WTR Symposium Series? “Critical Elements Mining and Processing Infrastructure Buildout – A Matter of National Security”. Read here! Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_ChemiMat_09302025 Part 2 included: @JindaleeL (JLL-ASX), @CriticalMetals_ (CRML), Tactical Resources Corp. (RARE-TSX), 5E Advanced Materials, Inc. (FEAM), and Atlas Lithium Corporation (ATLX) $JLL $CRML $RARE $FEAM $ATLX #SmallCap #Stocks #Investing
0 · Reply
LongerThanLong
LongerThanLong Sep. 30 at 2:32 PM
$AMGN together with $BIIB, $RARE, $DEO my favorite value plays these days. Won't get crazy rich but 10%+ should happen within a few months.
1 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 30 at 8:12 AM
$RARE Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) By Noor Ul Ain Rehman | September 30, 2025, 4:00 AM
0 · Reply
Airbags
Airbags Sep. 29 at 4:24 PM
$RARE does anyone know why this is popping today?
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Sep. 29 at 3:38 PM
$RARE A sign of life
1 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 8:49 AM
$RARE: Unusual Options Activity Alerted PUT flow observed 98x contracts at Strike price of $30 Exp on 12/19/2025 with Premium of $44K and showing NEUTRAL Sentiment
0 · Reply
Jphil07
Jphil07 Sep. 26 at 12:07 AM
$RARE price predictions if phase 3 orbit does well?
1 · Reply